Diabetes Mellitus, Left Ventricular Dysfunction
Conditions
Keywords
Diabetes Mellitus, Left Ventricular Dysfunction
Brief summary
This is a single-center, prospective, observational study to explore the clinical features and risk factors of impaired cardiac function detected by two-dimensional speckle tracking echocardiography in patients with diabetes mellitus. The risk factors include traditional cardiovascular risk factors, bone metabolism hormones, sex hormones, adrenal and pituitary hormones, and novel serum biomarkers.
Detailed description
Cardiovascular complications are a leading cause of death in patients with diabetes mellitus. However, early cardiovascular disease screening presents several challenges, particularly for those who have no cardiovascular symptoms. Novel imaging techniques, such as tissue Doppler imaging and speckle tracking echocardiography, allow for the more frequent detection of early subclinical left ventricular systolic dysfunction in asymptomatic patients with diabetes. Based on speckle tracking echocardiography and other techniques, this study evaluated cardiovascular function in diabetic subjects to achieve the following objectives: A) Investigate the clinical characteristics of diabetic patients with early cardiovascular function impairment. B) Investigate the role of traditional cardiovascular risk factors, bone metabolism hormones, sex hormones, adrenal and pituitary hormones in diabetic patients with early cardiovascular function impairment. C) Explore novel biomarkers of early cardiovascular dysfunction in diabetic patients.
Interventions
DIAGNOSTIC_TESTAssessment of cardiovascular risk factor, endocrine hormones and related biomarker
Cardiovascular risk factors: glycated hemoglobin/C-peptide/continuous glucose monitoring/blood pressure, blood lipids, uric acid, microalbumin test, etc. Endocrin hormones: bone metabolism, sex hormones, adrenal and pituitary hormones, and related biomarkers
Sponsors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Male or Female, aged ≥18 and ≤80 years. 2. Diagnosed type 2 or type 1 diabetes
Exclusion criteria
1. Moderate or severe valvular heart disease, history of thoracic surgery or congenital heart disease，atrial fibrillation. 2. History of coronary heart disease or stroke 3. Typical symptoms of cardiovascular disease（angina pectoris or limiting dyspnoea (\>NYHA II)） 4. LVEF \<60％ 5. Malignant tumor, acute infection, abnormal liver and kidney function (ALT \> normal upper limit 3 times or eGFR \< 60 ml/min/1.73 m2) 6. Diabetic ketoacidosis 7. Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of impaired cardiac function in type 2 diabetes diagnosed by echocardiography | Day 1 | Proportion of participants with GLS\>-18% in percent |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Glycaemic control measured by Continuous Glucose Monitoring System | Day 1 - Day 14 | Time in range in percent |
| Participants' personal information by questionnaire | Day 1 | Self-reported information(history of smoking) |
| BMI by physical assessments | Day 1 | BMI(body mass index) in kg/m\^2 |
| Waist by physical assessments | Day 1 | Waist in kg/m\^2 |
| Systolic blood pressure by physical assessments | Day 1 | Systolic blood pressure in mmHg |
| Diastolic blood pressure by physical assessments | Day 1 | Diastolic blood pressure in mmHg |
| Glycaemic control measured by blood test | Day 1 | HbA1c in % |
| Fasting glucose by blood test | Day 1 | Fasting glucose in mmol/l |
| Islet function measured by blood test | Day 1 | Fasting C-peptide in pmol/l |
| Low density lipoprotein cholesterol by blood test | Day 1 | Low density lipoprotein cholesterol in mmol/l |
| Total cholesterol by blood test | Day 1 | Total cholesterol in mmol/l |
| High density lipoprotein cholesterol by blood test | Day 1 | High density lipoprotein cholesterol in mmol/l |
| Masked hypertension diagnosed by ambulatory blood pressure monitoring | Day 13-Day 14 | Proportion of participants with a clinical condition in which a patient's office blood pressure (BP) level is \<140/90 mm Hg but ambulatory BP readings are in the hypertensive range in percent |
| Uric acids measured by blood test | Day 1 | Uric acids in umol/l |
| Bone metabolism hormones measured by blood test | Day 1 | Osteocalcin in ng/ml |
| Estradiol measured by blood test | Day 1 | Estradiol in pmol/l |
| Testosterone measured by blood test | Day 1 | Testosterone in nmol/l |
| Luteinizing hormone measured by blood test | Day 1 | Luteinizing hormone in mIU/ml |
| Follicle-stimulating hormone measured by blood test | Day 1 | Follicle-stimulating Hormone in mIU/ml |
| Insulin-like growth factor 1 measured by blood test | Day 1 | Insulin-like growth factor 1 in ng/ml |
| Cortisol measured by blood test | Day 1 | Cortisol in nmol/l |
| Adrenocorticotropic-hormone measured by blood test | Day 1 | Adrenocorticotropic-hormone in pmol/l |
| Biomarker measured by blood test | Day 1 | Brain natriuretic peptide in pg/ml |
| Triglycerides measured by blood test | Day 1 | Triglycerides in mmol/l |
Countries
China
Contacts
Primary ContactDalong Zhu, MD,PhD
Backup ContactRan Meng, MD,PhD
Outcome results
None listed